- Home
- OTLY vs FENC Comparison
OTLY vs FENC Comparison
Compare OTLY & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLY | FENC |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.5M | 411.0M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | OTLY | FENC |
|---|---|---|
| Price | $14.18 | $11.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $14.50 | $14.50 |
| AVG Volume (30 Days) | ★ 210.5K | 166.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $7.91 | $65.12 |
| Revenue Next Year | $5.50 | $41.08 |
| P/E Ratio | ★ N/A | $197.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.01 | $5.65 |
| 52 Week High | $18.84 | $13.25 |
Technical Indicators
Market Signals| Indicator | OTLY | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 59.14 |
| Support Level | $10.47 | $9.74 |
| Resistance Level | $15.77 | N/A |
| Average True Range (ATR) | 0.58 | 0.69 |
| MACD | -0.16 | 0.10 |
| Stochastic Oscillator | 52.01 | 63.42 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.